HGH Frag 176-191 (5 mg) – Targeted Fat-Burning Research Peptide
1. General Overview
HGH Frag 176-191 is a synthetic peptide that mimics a specific amino acid sequence (176–191) of the human growth hormone (HGH). This fragment is responsible for HGH’s fat-burning effects, offering enhanced lipolysis without significantly affecting blood sugar levels or promoting muscle growth.
2. Mechanism of Action
-
Stimulates Lipolysis: Accelerates the breakdown of stored fat.
-
Inhibits Lipogenesis: Reduces the formation of new fat cells.
-
Improves Insulin Sensitivity: Supports more efficient glucose utilization.
3. Key Research Benefits
-
Promotes rapid fat loss, particularly in stubborn areas.
-
Helps reduce subcutaneous fat without compromising muscle mass.
-
Enhances physical definition and endurance.
-
Provides mild anti-catabolic protection during caloric deficits.
4. Dosage & Administration
-
Recommended Dose: 250–500 mcg, 1–2 times per day.
-
Cycle Duration: 4–8 weeks (longer use may be considered under controlled conditions).
-
Route of Administration: Subcutaneous injection (commonly in abdominal fat).
-
Optimal Timing: Morning (fasted state) and/or pre-workout.
5. Possible Side Effects
Although generally well tolerated, some research subjects may observe:
-
Mild redness or irritation at the injection site.
-
Temporary gastrointestinal discomfort at higher doses.
-
Slight risk of hypoglycemia, especially when paired with a low-carb diet.
6. Research Stacking Options
-
For Enhanced Fat Loss: Combine with GHRP-6, CJC-1295, or Ipamorelin.
-
For Muscle Preservation: Stack with peptides that boost IGF-1 levels.
7. Product Specifications
-
Purity: ≥98% (HPLC-verified)
-
Form: Lyophilized powder (5 mg/vial)
-
Storage:
-
Lyophilized: Store at 2–8 °C.
-
Reconstituted: Refrigerate and use within 7 days.
-
Disclaimer: This product is intended for laboratory research purposes only. Not for human consumption, diagnostic, or veterinary use. Ensure compliance with all applicable regulations before use.
